Korro Bio, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Korro Bio, Inc. (KRRO) reported Revenue from Contract with Customer, Excluding Assessed Tax of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-10.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2023-03-10
- Korro Bio, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-12-31 was $0.00.
- Korro Bio, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-09-30 was $0.00.
- Korro Bio, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- Korro Bio, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Korro Bio, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Korro Bio, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $14.07M, a 61.96% decline from fiscal 2020.
- Korro Bio, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2020 was $36.98M, a 27.76% increase from fiscal 2019.
- Korro Bio, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2019 was $28.95M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $0.00 derived: sum of 2 quarters · filed 2023-03-10 | $0.00 derived: sum of 3 quarters · filed 2023-03-10 | $0.00 10-K · filed 2023-03-10 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | $0.00 derived: sum of 4 quarters · filed 2023-03-10 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | $0.00 derived: sum of 3 quarters · filed 2023-03-10 | $0.00 derived: sum of 4 quarters · filed 2023-03-10 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-04 | $0.00 derived: sum of 2 quarters · filed 2023-03-10 | $0.00 derived: sum of 3 quarters · filed 2023-03-10 | $9.42M derived: sum of 4 quarters · filed 2023-03-10 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $0.00 derived: sum of 2 quarters · filed 2023-03-10 | $9.42M derived: sum of 3 quarters · filed 2023-03-10 | $14.07M 10-K · filed 2023-03-10 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-08 | $9.42M derived: sum of 2 quarters · filed 2022-11-08 | $14.07M 10-Q · filed 2022-11-08 | $24.02M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $9.42M 10-Q · filed 2022-08-09 | $14.07M 10-Q · filed 2022-08-09 | $24.02M derived: sum of 3 quarters · filed 2022-08-09 | $35.27M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $4.65M 10-Q · filed 2022-05-04 | $14.60M derived: sum of 2 quarters · filed 2022-05-04 | $25.85M derived: sum of 3 quarters · filed 2022-05-04 | $34.37M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $9.95M 10-K · filed 2021-03-29 | $21.20M derived: sum of 2 quarters · filed 2021-11-15 | $29.72M derived: sum of 3 quarters · filed 2021-11-15 | $36.98M 10-K · filed 2022-03-15 |
| 2020-09-30 | $11.25M 10-Q · filed 2021-11-15 | $19.77M derived: sum of 2 quarters · filed 2021-11-15 | $27.03M 10-Q · filed 2021-11-15 | $31.74M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $8.52M 10-Q · filed 2021-08-12 | $15.79M 10-Q · filed 2021-08-12 | $20.50M derived: sum of 3 quarters · filed 2021-08-12 | $44.73M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $7.26M 10-Q · filed 2021-05-13 | $11.97M derived: sum of 2 quarters · filed 2021-05-13 | $36.21M derived: sum of 3 quarters · filed 2021-05-13 | |
| 2019-12-31 | $4.71M 10-K · filed 2021-03-29 | $28.95M derived: sum of 2 quarters · filed 2021-03-29 | $28.95M 10-K · filed 2021-03-29 | |
| 2019-09-30 | $24.24M 10-K · filed 2021-03-29 | $24.24M 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |